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Abstract: Since the introduction of HAART, there was a remarkably change in the natural history of HIV disease, leading 
to a notable extension of life expectancy, although prolonged metabolic imbalances could significantly act on the long-
term prognosis and outcome of HIV-infected persons, and there is an increasing concern about the cardiovascular risk in 
this population. Current recommendations suggest that HIV-infected perons undergo evaluation and treatment on the basis 
of the Third National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood 
Cholesterol in Adults (NCEP ATP III) guidelines for dyslipidemia, with particular attention to potential drug interactions 
with antiretroviral agents and maintenance of virologic control of HIV infection. While a hypolipidemic diet and physical 
activity may certainly improve dyslipidemia, pharmacological treatment becomes indispensable when serum lipid are 
excessively high for a long time or the patient has a high cardiovascular risk, since the suspension or change of an 
effective antiretroviral therapy is not recommended. Moreover, the choice of a hypolipidemic drug is often a reason of 
concern, since expected drug-drug interactions (especially with antiretroviral agents), toxicity, intolerance, effects on 
concurrent HIV-related disease and decrease patient adherence to multiple pharmacological regimens must be carefully 
evaluated. Often the lipid goals of patients in this group are not achieved by the therapy recommended in the current lipid 
guidelines and in this article we describe other possibilities to treat lipid disorders in HIV-infected persons, like 
rosuvastatin, ezetimibe and fish oil. 
Keywords:  Human immunodefciency virus, acquired immunodeficiency syndrome, highly active antiretroviral therapy, 
dyslipidemia, statins, fish oil, ezetimibe. 
INTRODUCTION 
  Disorders of lipid metabolism have been described in 
patients with HIV infection before the introduction of highly 
active antiretroviral therapy (HAART), including increased 
serum triglyceride (TG) levels and decreased cholesterol 
levels observed in advanced stages of HIV infection [1-3]. 
However, laboratory and clinical abnormalities of lipid 
metabolism have also been increasingly recognized after the 
advent of HAART. Significant increases in plasma TG and 
total cholesterol (TC) concentrations, often associated with 
abnormal body fat distribution and glucose metabolism 
alterations (such as peripheral insulin resistance, 
hyperinsulinemia, hyperglycemia and diabetes mellitus), 
have been reported specially in protease inhibitors (PI)- 
treated patients [4-6]. For details see Table 1. Since the 
introduction of HAART, there was a remarkably change in 
the natural history of HIV disease, leading to a notable 
extension of life expectancy, although prolonged metabolic 
imbalances could significantly act on the long-term 
prognosis and outcome of HIV-infected persons, and there is 
an increasing concern about the cardiovascular risk in this 
population [4,7,8]. While a hypolipidemic diet and physical 
activity may certainly improve dyslipidemia, 
pharmacological treatment becomes indispensable when   
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serum lipid are excessively high for a long time or the 
patient has a high cardiovascular risk, since the suspension 
or change of an effective antiretroviral therapy is not 
recommended [9]. Moreover, the choice of a hypolipidemic 
drug is often a reason of concern, since expected drug-drug 
interactions (especially with antiretroviral agents), toxicity, 
intolerance, effects on concurrent HIV-related disease and 
decrease patient adherence to multiple pharmacological 
regimens must be carefully evaluated [8,10]. HIV infected 
person have an increase risk of coronary artery disease 
(CAD) [11]. Part of this risk may be due to the 
hyperlipidemia associated with antiretroviral treatment 
[11,12]. Often the lipid goals of patients in this group are not 
achieved by the therapy recommended in the current lipid 
guidelines [3] and in this article we describe others 
possibilities to treat lipid disorders in HIV-infected persons. 
PATHOGENESIS FOR DYSLIPIDEMIA 
PIs- Associated Metabolic Alterations 
  PIs target the catalytic region of HIV-1 protease. This 
region is homologous with regions of two human proteins 
that regulate lipid metabolism: cytoplasmic retinoic-acid 
binding protein-1 (CRABP-1) and low density lipoprotein-
receptor-related protein (LRP) [13,14]. It is hypothesized 
that PIs inhibit CRABP-1-modified and cytrochrome P450 
3- mediated synthesis of cis-9 retinoic acid and peroxisome 
proliferator activated receptor (PPAR ) heterodimer. The 
inhibition increases the rate of apoptosis of adipocytes and 
reduces the rate at which pre-adipocytes differentiate into 32    The Open AIDS Journal, 2009, Volume 3  da Silva and Bárbaro 
adipocytes, with the final effect of reducing TG storage and 
increasing lipid release. PIs-binding to LRP would impair 
hepatic chylomicron uptake and endothelial TG clearance, 
resulting in hyperlipidemia and insulin resistance [13,14]. 
Table 1.  Changes in Lipid Metabolism in HIV Infection 
 
HIV-Infected Naïve Patients 
 Triglyceride 
 VLDL 
 VLDL triglyceride production rates 
Small, dense LDL 
HIV Patients Treated with IP Based Regimen 
 Triglyceride 
Total Cholesterol 
 VLDL, IDL, LDL-c, cholesterol     Postprandial delipidation 
 Apo B-100          VLDL to IDL/LDL transfer 
 Apo E          VLDL and LDL catabolic rates 
 ApoC-III          Hepatic lipase activity 
 VLDL production       Lipoprotein lipase activity 
VLDL - very low-density lipoprotein (LDL), HDL – high density lipoprotein, IDL – 
intermediate-density lipoprotein, Apo – apolipoprotein. 
 
  Some data indicate that PI-associated dyslipidemia may 
be caused, at least in part, by PI-mediated inhibition of 
proteasome activity and accumulation of the active portion 
of sterol regulatory element-binding protein (SREBP)-1c in 
liver cells and adipocytes or by apoliprotein (apo) CIII 
polymorphisms in HIV-infected persons [15]. The observed 
excess of apo CIII in lipoprotein might be a major 
determinant of a slower catabolism of triglyceride-rich 
lipoproteins because apo CIII is an inhibitor of lipoprotein 
lipase activity and also impairs the interaction of apo B and 
apo E with LDL receptor and LRP. This will result in an 
increased level of remnant lipoprotein returning to the liver 
[15,16]. Sequence homologies have been described between 
HIV-1 protease and human site-1 protease (S1P), which 
activates SREBP-1c and SREBP-2 pathways. A 
polymorphism in the S1P/SREBP-1c genes confers a 
difference in risk for development of an increase in TC with 
PI therapy, suggesting a possible genetic predisposition to 
hyperlipoproteinemia in PI-treated patients [17]. Caron et al. 
[17] reported that some PIs may impair the nuclear location 
of SREBP-1 and alter the structure and stability of the 
nuclear lamina possibly by impairing the maturation of 
prelamin A to lamin A. Lamin A and lamin C are encoded 
by the same gene and can combine with lamin B to form a 
network of filamentous proteins located at the inner face of 
the nuclear membrane called lamina [17]. Lamina interacts 
with the nuclear membrane and with chromatin. In 
particular, the C-terminal globular domain of lamin A/C can 
bind DNA and also SERBP-1 [17]. Cells from these patients 
have nuclear alterations and altered lamina stability, similar 
to the alterations induced in cultured adipocytes by some PIs 
[17]. It is possible to hypothesize that some PIs may alter the 
lamina structure and thereby alter the normal location of 
SREBP-1 inside the nucleus [17]. This could impair 
adipocyte differentiation and induce insulin resistance. 
Moreover, some PIs may alter the expression of 
adipocytokines in cultured adipocytes [18], increasing the 
expression of proinflammatory cytokines TNF- and IL-6, 
which are known to play a pathogenetic role in adipose 
tissue apoptosis and decreasing the expression of 
adiponectin, which is associated with the development of 
insulin resistance [18]. 
Treatment Considerations 
  The studies published until now show that dyslipidemia 
in HIV-infected persons carries the same degree of 
cardiovascular risk as in HIV-negative population [19]. 
Nowadays the benefits of lipid-lowering interventions have 
been extended to HIV-infected persons. Further, there is 
currently no basis for a more aggressive intervention among 
HIV-infected persons than what is currently recommended 
for the general population. Because there is a significant 
possibility for drug interaction of some lipid-lowering agents 
with antiretroviral drugs (in particular statins are metabolized 
through the cytochrome (CYP) P450 system), care should be 
given to the choice of lipid-lowering agents. Current 
recommendations suggest that HIV-infected persons undergo 
evaluation and treatment on the basis of the Third National 
Cholesterol Education Program Expert Panel on Detection, 
Evaluation and Treatment of High Blood Cholesterol in 
Adults (NCEP ATP III) guidelines for dyslipidemia, with 
particular attention to potential drug interactions with 
antiretroviral agents and maintenance of virologic control of 
HIV infection. Nonpharmacologic measures remain the basis 
for intervention. The initial choice for hypertriglyceridemia 
is fibrate, and for elevated LDL-c, statins [20]. 
  According to the US-based Adult AIDS Clinical Trial 
Group (AACTG) Cardiovascular Disease Focus Group, 
treatment with pravastatin, fluvastatin or atorvastatin is 
recommended for antiretroviral-linked hypercholesterolemia, 
while lovastatin and simvastatin should be avoided due to 
interactions with PIs or non-nucleoside reverse transcriptase 
inhibitors (NNRTI) [21] and the risk of skeletal muscle 
toxicity. Many studies that evaluate the effect of statins for 
the treatment of antiretroviral-associated dyslipidemia have 
shown only partial responses to such therapy, with total and 
LDL-c values being reduced by just 25% [22]. 
  Statins are considered the current first-line therapy for 
primary hypercholesterolemia and showed beneficial effects 
in both reducing total and LDL-c cholesterol levels in the 
HIV-negative persons [23]. Because of the variable 
metabolism through CYP 3A4, significant interactions have 
been documented with potent CYP 3A4 inhibitors (such as 
itraconazole, cyclosporine, oral anticoagulants, PIs and 
delaverdine), which cause elevated levels of statins, leading 
to a significantly increase of liver and skeletal muscle 
toxicity [23]. Lovastatin and simvasatin are administered as 
inactive lactone prodrugs that are avidly metabolized by 
intestinal and hepatic CYP 3A4. On the other hand, 
pravastatin, atorvastatin and fluvastatin are administered 
directly as the active hydroxyl-acid. Pravastatin is eliminated 
mostly by glucoronidation, fluvastatin by CYP 2C9 isoform, 
and CYP 3A4 has no role in their metabolism [24]. On the 
basis on the clinical and experimental data, simvastin and 
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NNRTIs, atorvastatin can be used with caution (at low initial 
doses) and pravastatin and fluvastatin appear to be safe for 
use in association with HAART [19]. Table 2 has a summary 
of the lipid lowering therapy in HIV infected persons. 
Rosuvastatin 
  Rosuvastatin is a 3-hydroxy-3-methylglutaryl coenzyme 
A (HMG-CoA) inhibitor that showed the highest dose-to-
dose potency in lowering total and LDL-c levels, compared 
with other currently available statins. It works also to reduce 
TG and increase HDL-c. Moreover, pharmacokinetic studies 
have demonstrated that its metabolism is not dependent on 
the CYP 450 3A4 isoenzyme and its use could be considered 
in PI-treated individuals as the result of the low risk of drug-
drug interactions [25]. Only 10% of the administered dose is 
metabolized by CYP 2C9 isoenzyme into N-desmethyl 
rosuvastatin and its metabolite are 90% eliminated by the 
fecal route [24-26]. The usual recommended starting dose of 
rosuvastatin is 10 mg daily, but initiation at 5 mg daily may 
be considered for patients who have predisposing factors for 
myopathy or are taking cysclosporine. In subjects with 
severe renal impairment or taking fibrates, therapy with 
rosuvastatin should only be used with great caution, daily 
dose should be initiated at 5 mg and not exceed 10 mg [26]. 
  In the research of Bottero et al. [27], the use of 
rosuvastatin (10 mg/day) was retrospective evaluated during 
16 weeks in HAART-treated HIV-infected persons with 
dyslipidemia. Seventy eight patients started on rosuvastatin, 
sixty as monotherapy. After 16 weeks of treatment, a 
significant decrease was seen in both LDL-c and non-HDL 
(31,3% and 29,9% reduction respectively). The decrease in 
triglyceride was also significant (34,1%). Rosuvastatin was 
safe and effective in the treatment of dyslipidemia in 
HAART-treated HIV-infected persons. The results showed 
above are similar to the HIV-uninfected population. Calza et 
al.  [28] in an open label, randomized, prospective study 
evaluated the role of rosuvastatin (10 mg once daily), 
pravastatin (20 mg once daily) and atorvastatin (10 mg once 
daily) in the treatment of hypercholesterolemia (TC > 250 
mg/dL) in HIV-infected persons at least 3 month duration 
and unresponsive to a hypolipidemic diet and physical 
exercise. Eighty five subjects completed the study and the 
mean reduction after one year follow up was 21,2% and 
23,6% versus baseline TC and LDL-c levels, respectively 
(p=0.002). Mean decrease in TC concentration was 
significantly greater with rosuvastatin (25,2%) than with 
pravastatin (17,6% p = 0.01) and atorvastatin (19,8% p = 
0.03). All the statins showed a favourable tolerability profile, 
but rosuvastatin was found to be more effective. Van der Lee 
et al. [29] evaluated the pharmacokinectics and 
pharmacodynamics of combined use of lopinavir/ritonavir 
and rosuvastatin (10 mg, 20 mg and 40 mg) in HV-infected 
persons and found that the levels of this PI were not affected 
by the administration of rosuvastatin, but the rosuvastin 
levels unexpectedly appeared to be 1.6 fold compared with 
healthy volunteers. Larger studies are necessary to confirm 
these findings, until there, the combination of rosuvastin and 
lopinavir/ritonavir should be used with caution. 
Ezetimibe 
  Ezetimibe is the first lipid-lowering drug that inhibits 
intestinal uptake of dietary and biliary cholesterol at the 
brush border of the intestine, resulting in a reduction of 
hepatic cholesterol stores and an increase in clearance of 
cholesterol form in the blood [30]. It doesn’t affect the 
absorption of fat-soluble nutrients and is an attractive option 
for HIV-infected persons because it lacks CYP P450 
metabolism and therefore is not expected to interact with 
antiretroviral [30,31]. It reduces cholesterol absorption in the 
duodenum by approximately 50%, thereby attaining 
reductions in LDL-c of 20% [32]. This benefit is 
significantly greater when it is given with any of the statins, 
achieving reductions in LDL-c of up to 50% [32,33]. This 
synergistic effect of the two drugs in combination results 
from the inhibition of duodenal cholesterol absorption by 
ezetimibe, together with the reduction of hepatic cholesterol 
production by the statins [30]. Following oral administration, 
Table 2.  Lipid Lowering Therapy for HIV-Infected People 
 
Lipid Alteration  Therapy  Caution 
Elevated LDL-c or 
non-HDL 
cholesterol with 
triglycerides level of 
200-500 mg/dL 
Statins: 
-  Pravastatin: 20-40 mg daily 
-  Atorvastatin: 10-20 mg/daily 
-  Fluvastatin: 20-40 mg/daily 
-  Rosuvastatin 
-  Lovastatin 
-  Simvastatin 
-  Ezetimibe: 10 mg daily  
 
Less drug interaction potential 
Used with caution in lower doses when combined with PIs and NNRTIs 
Minimal drug interaction potential. Not widely used due to low potency 
Most potent statin. May be used safely with antiretroviral 
Avoid in patients taking PIs 
Avoid in patients taking PIs or delaverdine 
Can be used with statin or in monotherapy 
triglycerides level > 
500 mg/dL 
Fibrates and Fish Oil: 
-  Gemfibrozil: 1200 mg daily 
-  Fenofibrate: 200 mg daily 
-  Bezafibrate: 400 mg daily 
-  Omega-3 polyunsaturated fatty 
acids/fish oil: 3-5g 
 
Caution when used with statins in mixed dyslipidemia 
Caution when used with statins in mixed dyslipidemia 
First line therapy for hypertriglyceridemia 
Evidence suggest fish oil may decrease triglycerides and increase HDL-c, 
however can also increase LDL-c 
Adapted from Bennet M [38], Stebbing J [39], Calza L [53], Soler A [54], Bader MS [55]. 34    The Open AIDS Journal, 2009, Volume 3  da Silva and Bárbaro 
ezetimibe is rapidly absorbed and extensively metabolized 
(>80%) to the pharmacologically active ezetimibe-
glucuronide [30]. The recommended dose is 10 mg/day, and 
can be administered in the morning or evening without 
regard to food [30]. The major metabolic pathway for 
Ezetimibe consists of glucuronidation of 4-hydroxyphenyl 
group by uridine 5’-diphosphate-glucuronosyltransferase 
isoenzymes to form ezetimibe-glucuronide in the intestine 
and liver [30]. It has a favourable drug-drug interaction 
profile. Ezetimibe does not have significant effects on 
plasma levels of HMG-CoA reductase inhibitors known as 
statins (atorvastatin, fluvastatin, lovastatin, pitavastatin, 
pravastatin, rosuvastatin, simvastatin), fibric acid derivatives 
(gemfibrozil, fenofibrate), digoxin, glipizide, warfarin and 
triphasic oral contraceptives (ethinylestradiol and 
levonorgestrel). Concomitant administration of food, 
antiacids, cimetidine or statins had no significant effect on 
ezetimibe bioavailability [34]. 
  Ezetimibe has been effective in optimizing lipid levels 
when added to traditional therapy in non-HIV infected 
persons [34-36]. In HIV positive population some studies 
have assessed the efficacy of this drug and are described as 
follow. Coll et al. [37] showed that ezetimibe monotherapy 
decreases LDL-c as effectively as fluvastatin monotherapy. 
Twenty HIV-infected persons were randomly assigned to 
receive ezetimibe (10 mg/day) or fluvastatin (80 mg/day). 
Patients receiving ezetimibe experienced a statistically 
significant (p=0,003) 20% reduction in the concentration of 
LDL-c, similar to that observed with fluvastatin (24%, p 
between groups 0.70). Negredo et al. [30] conducted a 
prospective study and Ezetimibe was added when the statin 
(pravastatin monotherapy) has poor response. During 24 
weeks, nineteen patients received ezetimibe (10mg/day) and 
pravastatin (20 mg/day), while the patients maintained the 
same antiretroviral regimen. At week 24, 61,5% of patients 
achieved the endpoint of the study (LDL-c < 130 mg/dL). 
Significant declines in total and LDL-c levels were observed 
between baseline and weeks 6, 12, 24, irrespective of 
antiretroviral regimen (IP or ITRNN) and mean HDL-c 
increased significantly. No patients discontinued therapy due 
to intolerance or toxicity. The addition of ezetimibe to 
ongoing pravastin was effective and a safe option for HIV-
infected persons not achieving the NCEP ATP III LDL-c 
goals despite receiving a statin alone. Bennet et al. [38], 
added ezetimibe to maximally tolerated lipid lowering 
therapy (statins or fenofibrate) in 33 HIV infected persons. 
The mean TC and LDL-c were reduced 21% and 35% 
respectively (p <0.001) and HDL-c increased 8% (p=0.038). 
No adverse events occurred. Stebbin et al. [39] analyzed 
twenty nine HIV-infected persons with ezetimibe alone or 
associated with statins. Of these individuals, 16 and 11 
respectively were receiving PI-based and NNRTI-based 
regimen. During 12 weeks, it was observed a significant 
reduction of 18% in TC (p<0.01) and 28,9% in TG (p<0.05) 
regardless of whether patients received statins or not, or the 
type of antiretroviral therapy. In the end of study, 40% of the 
patients had normalized serum TC, but the same didn’t occur 
with TG. There were no significant differences in reduction 
of either serum TC or TG in those receiving ezetimibe alone 
(n =12) or combined with statins (n= 17). The limitations of 
this study included small sample size and lack of 
measurement of LDL-c level. Van den Berg-Wolf et al. [40] 
in a prospective, non controlled study, evaluated twenty 
HIV-infected persons who were on treatment with statins 
and didn’t reach the LDL-c goal during 18 weeks. These 
patients were on HAART that included ritonavir-boosted PIs 
in 17 (85%) and 3 (15%) on nelfinavir. Mean percentage of 
changes from baseline in LDL-c were: - 10,9%, - 12,2% and 
– 9,1% at weeks 6,12,18, respectively (p<0.05 at each time 
period vs baseline). No significant changes in TG and HDL-c 
were seen. In a subgroup of patients on lopinavir/ritonavir 
(LPV/r), the concentrations of the drug were obtained before 
and after the introduction of Ezetimibe and no significant 
changes were observed in the concentration of this PI. 
  Ezetimibe could be recommended as a second line 
therapy to HAART induced dyslipidemia if hypercholesterolemia 
is refractory to the statins or if the patient does not tolerate 
these drugs. Its high tolerability and the lack of interactions 
with the CYP 3A4 indicate that ezetimibe will not increase 
the risk of toxicity or pharmacokinetic interactions with 
antiretroviral. 
Fish Oil 
  The metabolic effects of N-polyunsaturated fatty acids 
(PUFAs) derived from marine sources (so-called “fish oils”) 
have been demonstrated to reduce fasting and postprandial 
TG levels in subjects without HIV infection [41]. Omega-3 
is considered an alternative treatment in non-HIV infected 
persons. Interest in the triglyceride-lowering effect of 
omega-3 fatty acids first came from studies in Greenlandic 
Eskimos, which showed that, despite high intake of animal 
fats, there was low incidence of CAD. A contributing factor 
was the type of fats being consumed, which were rich in 
omega-3 fatty acids [42,43] however the exact mechanism 
whereby these fats decrease the risk of CAD is unclear. It 
has been demonstrated that 3-5 g per day of omega-3 fatty 
acids can reduce triglycerides by 30-50%, thereby potentially 
minimizing the risk of coronary heart disease (CHD) and 
pancreatitis [44]. Intake of small amounts of fish has also 
been shown to affect mortality [44]. One research showed 
that, in addition to significantly lowering plasma levels of 
TC, LDL-c and VLDL-c, salmon oil and other omega-3-
enriched fish oils can have a potentially therapeutic role in 
the treatment of very high plasma TG levels [45-48]. Few 
data are available on the effect of PUFAs on metabolic 
abnormalities in HIV persons [49] however recent studies 
suggest possible efficacy and safety of fish oil 
supplementation in the treatment of antiretroviral therapy-
associated hypertriglyceridemia [50]. 
 Whol  et al. [50] conducted an open-label, randomized 
trial with 52 patients receiving HAART with fasting TG 
levels of > 200 mg/dL to receive nutritionist-administered 
dietary and exercise counseling with or without fish oil 
supplementation for 16 weeks. Patients assigned to receive 
fish oil had a 25% decline in fasting TG levels at week 4 
(95%CI, - 34.6% to - 15.7% change), compared with a 2.8% 
mean increase among patients assigned to receive counseling 
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week 16, the mean reduction in TG levels in the fish oil arm 
remained significant at 19.5% (95% CI, - 34.9% to – 4.0 % 
change), whereas the mean decrease in the diet and exercise 
only arm was 5.7% (95% CI – 24.6% to + 13.2% change); 
however, the difference between study arms was no longer 
statistically significant (p=.12). Low density lipoprotein 
cholesterol levels had increased by 15.6% (95% CI, + 4.8% 
to + 26.4 % change), at week 4 and by 22.4% (95% CI, + 
7.91% to + 36.8 % change) at week 16 in the fish oil arm but 
did not change in the other group. Carter et al. [51] 
compared the effectiveness of omega-3 fatty acid 
supplementations and placebo in lowering TG levels in HIV-
infected persons on HAART. It was a placebo-controlled, 
randomized, double-blind trial in participants with stable 
HAART with fasting TG > 312 mg/dL* to 890 mg/dL* 
using 9 g of omega-3 fatty acids versus placebo (olive oil) 
after 6 week lead in on dietary therapy. Eleven HIV-infected 
males were enrolled. The mean TG level decreased from 447 
mg/dL* at baseline to 395 mg/dL* (- 11.6%) after dietary 
intervention and to 300 mg/dL* (-32.9%) after 8-week 
treatment period. In the omega-3 fatty acid arm, TG fell from 
475 mg/dL to 447mg/dL* (- 6%) after dietary intervention 
and to 210 mg/dL* (- 56.9%) after treatment period. In the 
placebo arm, TG fell from 425 mg/dL to 361 mg/dL*   
(- 15.1%) after dietary intervention and to 363 mg/dL*   
(- 14.5%) after the treatment period. The difference between 
the groups was significant (p=0.0487). The estimated 
difference between groups for change in mean TG over 8-
weeks was - 207 mg/dL* (CI 95% - 402 to - 11 mg/dL). De 
Truchis et al. [52] evaluated the TG levels in HIV-infected 
persons receiving stable antiretroviral therapy treated with 
PUFAs in a prospective double-blind randomized design. 
One hundred twenty two patients with TG > 200 mg/dL* and 
 1000 mg/dL* after 4-week diet were randomized for 8-
weeks to N-3 PUFAs (2 capsules containing 1g of fish oil 3 
times daily, n=60) or placebo (1g of paraffin oil capsules, 
n=62). An 8-week open-label phase of N-3 PUFAs followed. 
The difference (PUFA versus placebo) in TG percent change 
at week 8 was – 24.6% (range: -40.9% to – 8.4%; p = 
0.0033), the median was - 25.5% in the PUFA group versus 
1% in placebo group and mean TG levels at week 8 were 
340 ±180 mg/dL* and 480 ± 310 mg/dL* respectively. The 
TG levels were normalized in 22.4% (PUFA) versus 6.5% 
(placebo) (p=0.013) with a  20% reduction in 58.6% 
(PUFA) versus 33.9% (placebo) (p=0.007). Under the open-
label phase of N-3 PUFAs, the decrease in TG levels was 
sustained at week 16 for patients in the PUFA group (mean 
TG levels: 340 ± 170 mg/dL*, whereas a 21.2% decrease in 
TG levels occurred in the placebo group (mean TG levels: 
330 ± 140 mg/dL*. The median TG change at week 8 was - 
43.6% (range Q1-Q3; 95% CI: - 66.5% to – 4.6%) for 
patients with TG levels > 1000 mg/dL. Manfredi et al. [49] 
in a prospective, open-label study, evaluated the efficacy and 
safety profile of polyunsaturated ethyl esters of n-3 fatty 
acids (PEEs) in the control of moderate hypertriglyceridemia 
complicating antiretroviral-treated HIV disease, compared 
with diet and exercise and with fibrate. Patients with 
moderate hypertriglyceridemia (200-500 mg/dL) while on 
HAART, despite modified diet and increased physical 
activity were selected. A total of 156 patients aged 36-62 
years (97 men) were evaluated. Fifty four patients received 
PEE at 1g twice daily; 53 subjects were treated with standard 
doses of either: bezafibrate (21 cases), fenofibrate (19 cases) 
or gemfibrozil (13 cases); and the remaining 49 patients 
continued a diet-exercise program and served as controls. An 
analysis of 18 months showed that continued PEE 
administration led to a significant decrease of mean TG of 
5.6; 15.8, 13.3, 16; 15.3 and 11.6% after 3, 6, 9, 12, 15 and 
18 months, respectively (P<0.0001 vs baseline levels), while 
negligible changes occurred in serum cholesterolemia. Both 
PEE and fibrate administration achieved a significant (p< 
0.0001) amelioration of triglyceridemia compared with diet-
exercise only, although fibrates showed a better efficacy 
profile vs PEE (p < 0.0001); these significance levels were 
maintained throughout the entire 18-month observation 
period. When comparing the efficacy of PEE with that of a 
diet-exercise program, a significant difference was reached 
at the 6
th month (p=0.001) and was maintained until the 18
th 
month (p=0.005 – P< 0.0001). It showed that pharmaceutical 
interventions for extreme hyperlipidaemia will continue to 
be superior to dietary therapy alone and that omega-3 fatty 
acid will be a useful additional intervention in HIV-infected 
people with hypertriglyceridemia. 
CONCLUSION 
  All HIV-infected persons should have their fasting 
plasma lipid profile prior to starting HAART. These exams 
should be repeated 2 to 3 months after starting or changing 
antiretroviral therapy, every 2 to 3 months with the existing 
of significant abnormalities and to assess response to lipid-
lowering therapy. It should be checked annually in the 
absence of significant abnormalities or well-achieved targets 
as a result of intervention. Efforts should be used including 
lifestyle modification and lipid-lowering agents if it is 
necessary, to achieve lipids goals. Special attention should 
be given to drug interactions between lipid-lowering agents 
and antiretroviral therapy. Neither, lovastatin or simvastatin 
should be used with PI and atorvastatin should be used with 
caution. Rosuvastatin is a new statin with promising results 
in HIV-infected people. Ezetimibe is the first lipid-lowering 
drug that inhibits intestinal uptake of dietary and biliary 
cholesterol at the brush border of the intestine and researches 
showed that it could be used as monotherapy or combined 
with statin. Omega-3 is considered an alternative treatment 
in non-HIV infected populations and that this fish oil could 
be used to treat high TG levels related to HAART. 
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